Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | HCK | P08631 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.41 |
| ▸ | PRKDC | P78527 | 2/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711678 | 0.89 | BUB1 (0.42) | ACLYPIK3CDABL1EGFRHCK | |
| SCHEMBL7218364 | 0.89 | BUB1 (0.42) | ACLYPIK3CDABL1EGFRHCK | |
| SCHEMBL8504655 | 0.86 | PARP1 (0.43) | ACLYPIK3CDABL1EGFRHCK | |
| SCHEMBL819797 | 0.81 | PIK3CD (0.46) | ACLYPIK3CDABL1EGFRHCK | |
| SCHEMBL18805035 | 0.81 | PIK3CD (0.46) | ACLYPIK3CDABL1EGFRHCK | |
| SCHEMBL19643970 | 0.79 | GSK3B (0.53) | ABL1 | |
| SCHEMBL30285159 | 0.79 | PIK3CD (0.42) | ACLYPIK3CDABL1EGFRHCK | |
| SCHEMBL31424162 | 0.79 | ACLY (0.43) | ACLYPIK3CDABL1EGFRHCK | |
| SCHEMBL30147588 | 0.79 | ACLY (0.43) | ACLYPIK3CDABL1EGFRHCK | |
| SCHEMBL1373109 | 0.79 | HTR6 (0.46) | ACLYPIK3CDABL1EGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391602-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| CN-102325753-A | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2012-01-18 | — | — | CN | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| EP-0821685-B1 | INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LAB (US) | 2001-10-04 | — | — | EP | disclosed |
| US-5654305-A | TREATING PLATELET ACTIVATING FACTOR MEDIATED DISORDERS | ABBOTT LABORATORIES (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996033196-A1 | INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5567711-A | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1996-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | ACLY 4286/4885HDAC2 359/4885HDAC1 499/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | ACLY 4286/4885HDAC2 359/4885HDAC1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.